Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 1, 2007, Pages 1-8

  Ito, Kazuhiro ^a   Caramori, Gaetano ^b   Adcock, Ian M ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; AS 604850; CAFFEINE; CBL 1309; CORTICOSTEROID; FURAN 2 YLMETHYLENE THIAZOLIDINEDIONE DERIVATIVE; IC 87114; ISOENZYME; METHYLXANTHINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; PX 866; SF 1126; SH 5; THEOPHYLLINE; UNCLASSIFIED DRUG; WORTMANNIN; YM 024; ZSTK 474;

ASTHMA; CATALYSIS; CELL FUNCTION; CELL MIGRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY CELL; NONHUMAN; OXIDATIVE STRESS; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT DISEASE; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; CELL MOVEMENT; ENZYME INHIBITORS; HUMANS; INFLAMMATION; LYMPHOCYTES; OXIDATIVE STRESS; RESPIRATORY TRACT DISEASES; SIGNAL TRANSDUCTION;

EID: 33947358942     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.111674     Document Type: Review

References (43)

1. Adcock IM, Chung KF, Caramori G, and Ito K (2006) Kinase inhibitors and airway inflammation. Eur J Pharmacol 533:118-132.
2. Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C, Kuehn N, Gray A, Giddings J, Peskett E, et al. (2004) Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature (Lond) 431:1007-1011.
3. Barnes PJ (2003) New concepts in chronic obstructive pulmonary disease. Annu Rev Med 54:113-129.
4. Barnes PJ and Kleinert S (2004) COPD-a neglected disease. Lancet 364:564-565.
5. Barnes PJ, Shapiro SD, and Pauwels RA (2003) Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 22:672-688.
6. 2-induced apoptosis through functional codependence between HO-1 and AKT. Arterioscler Thromb Vasc Biol 26:2027-2034.
7. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Francon B, et al. (2005) Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 11:936-943.
8. Curnock AP, Logan MK, and Ward SG (2002) Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases. Immunology 105:125-136.
9. Del PA, Vermi W, Dander E, Otero K, Barberis L, Luini W, Bernasconi S, Sironi M, Santoro A, Garlanda C, et al. (2004) Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice. EMBO (Eur Mol Biol Organ) J 23:3505-3515.
10. Domin J, Harper L, Aubyn D, Wheeler M, Florey O, Haskard D, Yuan M, and Zicha D (2005) The class II phosphoinositide 3-kinase PI3K-C2beta regulates cell migration by a PtdIns3P dependent mechanism. J Cell Physiol 205:452-462.
11. Duan W, Guinaldo Datiles AM, Leung BP, Vlahos CJ, and Wong WS (2005) An anti-inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model. Int Immunopharmacol 5:495-502.
12. Ezeamuzie CI, Sukumaran J, and Philips E (2001) Effect of wortmannin on human eosinophil responses in vitro and on bronchial inflammation and airway hyperresponsiveness in Guinea pigs in vivo. Am J Respir Crit Care Med 164:1633-1639.
13. Foukas LC, Daniele N, Ktori C, Anderson KE, Jensen J, and Shepherd PR (2002) Direct effects of caffeine and theophylline on p110 delta and other phosphoinositide 3-kinases. Differential effects on lipid kinase and protein kinase activities. J Biol Chem 277:37124-37130.
14. Fukao T and Koyasu S (2003) PI3K and negative regulation of TLR signaling. Trends Immunol 24:358-363.
15. Helgason CD, Damen JE, Rosten P, Grewal R, Sorensen P, Chappel SM, Borowski A, Jirik F, Krystal G, and Humphries RK (1998) Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev 12:1610-1620.
16. Hennessy BT, Smith DL, Ram PT, Lu Y, and Mills GB (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4:988-1004.
17. Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, and Adcock IM (2002) p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 109:649-657.
18. Ito K (2005) Corticosteroid resistance in COPD, in Chronic Obstructive Pulmonary Disease (Barnes PJ ed) pp 367-389, Taylor & Francis, London.
19. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, et al. (2005) Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 352:1967-1976.
20. Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ, and Adcock IM (2006) Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression. J Exp Med 203:7-13.
21. Ko HM, Kang JH, Choi JH, Park SJ, Bai S, and Im SY (2005) Platelet-activating factor induces matrix metalloproteinase-9 expression through Ca(2+)- or PI3K-dependent signaling pathway in a human vascular endothelial cell line. FEBS Lett 579:6451-6458.
22. Koyasu S (2003) The role of PI3K in immune cells. Nat Immunol 4:313-319.
23. Kozikowski AP, Sun H, Brognard J, and Dennis PA (2003) Novel PI analogues selectivity block activation of the pro-survival serine/threonine kinase Akt. J Am Chem Soc 125:1144-1145.
24. Kwak YG, Song CH, Yi HK, Hwang PH, Kim JS, Lee KS, and Lee YC (2003) Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma. J Clin Investig 111:1083-1092.
25. Lee KS, Kim SR, Park SJ, Lee HK, Park HS, Min KH, Jin SM, and Lee YC (2006a) Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) reduces vascular endothelial growth factor expression in allergen-induced airway inflammation. Mol Pharmacol 69:1829-1839.
26. Lee KS, Lee HK, Hayflick JS, Lee YC, and Puri KD (2006b) Inhibition of phosphoinositide 3-kinase delta attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J 20:455-465.
27. Lee SB, Cho ES, Yang HS, Kim H, and Um HD (2005) Serum withdrawal kills U937 cells by inducing a positive mutual interaction between reactive oxygen species and phosphoinositide 3-kinase. Cell Signal 17:197-204.
28. Maffucci T, Cooke FT, Foster FM, Traer CJ, Fry MJ, and Falasca M (2005) Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J Cell Biol 169:789-799.
29. Mo B, Zhang Z, Xu Y, Xiong W, Liu XA, and Zhen G (2005) Expression of heme oxygenase-1 in the peripheral blood mononuclear cells from asthmatic patients. J Huazhong Univ Sci Technolog Med Sci 25:385-388.
30. Pomel V, Klicic J, Covini D, Church DD, Shaw JP, Roulin K, Burgat-Charvillon F, Valognes D, Camps M, Chabert C, et al. (2006) Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J Med Chem 49:3857-3871.
31. Powis G, Ihle N, and Kirkpatrick DL (2006) Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway. Clin Cancer Res 12:2964-2966.
32. Puri KD, Doggett TA, Douangpanya J, Hou Y, Tino WT, Wilson T, Graf T, Clayton E, Turner M, Hayflick JS, et al. (2004) Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking into inflamed tissue. Blood 103:3448-3456.
33. Qin S and Chock PB (2003) Implication of phosphatidylinositol 3-kinase membrane recruitment in hydrogen peroxide-induced activation of PI3K and Akt. Biochemistry 42:2995-3003.
34. Rahman I and Adcock IM (2006) Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 28:219-242.
35. Rauh MJ, Kalesnikoff J, Hughes M, Sly L, Lam V, and Krystal G (2003) Role of Src homology 2-containing-inositol 5′-phosphatase (SHIP) in mast cells and macrophages. Biochem Soc Trans 31:286-291.
36. Rojo AI, Salina M, Salazar M, Takahashi S, Suske G, Calvo V, de Sagarra MR, and Cuadrado A (2006) Regulation of heme oxygenase-1 gene expression through the phosphatidylinositol 3-kinase/PKC-zeta pathway and Sp1. Free Radic Biol Med 41:247-261.
37. Shahabuddin S, Ji R, Wang P, Brailoiu E, Dun N, Yang Y, Aksoy MO, and Kelsen SG (2006) CXCR3 chemokine receptor-induced chemotaxis in human airway epithelial cells: role of p38 MAPK and PI3K signaling pathways. Am J Physiol 291:C34-C39.
38. Thomas MJ, Smith A, Head DH, Milne L, Nicholls A, Pearce W, Vanhaesebroeck B, Wymann MP, Hirsch E, Trifilieff A, et al. (2005) Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases. Eur J Immunol 35:1283-1291.
39. Tsoumakidou M, Tzanakis N, Chrysofakis G, and Siafakas NM (2005) Nitrosative stress, heme oxygenase-1 expression and airway inflammation during severe exacerbations of COPD. Chest 127:1911-1918.
40. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, and Foukas LC (2005) Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 30:194-204.
41. Ward SG and Finan P (2003) Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr Opin Pharmacol 3:426-434.
42. Ward S, Sotsios Y, Dowden J, Bruce I, and Finan P (2003) Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem Biol 10:207-213.
43. Wymann MP, Bjorklof K, Calvez R, Finan P, Thomast M, Trifilieff A, Barbier M, Altruda F, Hirsch E, and Laffargue M (2003) Phosphoinositide 3-kinase gamma: a key modulator in inflammation and allergy. Biochem Soc Trans 31:275-280.